Alkermes plc (ALKS) 10-Year Financial Performance & Capital Metrics

ALKS •

HealthcareBiotechnologyCommercial Specialty Pharma

AboutAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Show more

Revenue $1.48B -5.2%
EBITDA $281M -37.4%
Net Income $242M -34.2%
EPS (Diluted) 1.43 -34.1%
Gross Margin 86.31% +2.4%
EBITDA Margin 19.05% -33.9%
Operating Margin 17.21% -36.3%
Net Margin 16.37% -30.5%
ROE 14.72% -46.5%
ROIC 14.94% -44.0%
Debt/Equity 0.04 -25.4%
Interest Coverage 20.69 +11.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Excellent 3Y average ROE of 24.6%

✗Weaknesses

✗Low quality earnings: Net income not backed by cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y8.91%

5Y7.28%

3Y9.9%

TTM-5.25%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-34.16%

EPS CAGR

10Y-

5Y-

3Y-

TTM-34.1%

ROCE

10Y Avg2.39%

5Y Avg14.69%

3Y Avg22.49%

Latest14.37%

Peer Comparison

Commercial Specialty Pharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ALKSAlkermes plc	4.98B	30.10	21.05	-5.25%	16.37%	13.28%	0.01%	0.04
ADMAADMA Biologics, Inc.	3.71B	15.57	19.22	65.15%	42.87%	48.57%	2.97%	0.24
UTHRUnited Therapeutics Corporation	21.99B	503.90	18.09	10.61%	41.94%	18.81%	4.73%
PCSAProcessa Pharmaceuticals, Inc.	114.71M	2.17	-0.56			-221.71%		0.04
UNCYUnicycive Therapeutics, Inc.	144.49M	6.93	-1.24	-100%		-89.15%		0.10
PTHSPelthos Therapeutics Inc.	85.29M	26.36	-1.95		-318.41%	-40.48%
MISTMilestone Pharmaceuticals Inc.	145.64M	1.71	-2.55	-100%		-282.97%		4.17
AMRNAmarin Corporation plc	5.74B	13.80	-3.45	-25.51%	-38.01%	-18.78%		0.02

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	745.69M	903.37M	1.09B	1.17B	1.04B	1.17B	1.11B	1.66B	1.56B	1.48B
Revenue Growth %	18.68%	21.15%	21.13%	7.01%	-11.29%	13%	-5.28%	49.61%	-6.36%	-5.25%
Cost of Goods Sold+	132.12M	154.75M	176.42M	180.38M	178.32M	197.32M	218.07M	253.04M	245.33M	202.06M
COGS % of Revenue	17.72%	17.13%	16.12%	15.41%	17.17%	16.81%	19.61%	15.21%	15.75%	13.69%
Gross Profit+	613.57M	748.63M	917.85M	990.56M	860.44M	976.43M	893.73M	1.41B	1.31B	1.27B
Gross Margin %	82.28%	82.87%	83.88%	84.59%	82.83%	83.19%	80.39%	84.79%	84.25%	86.31%
Gross Profit Growth %	25.39%	22.01%	22.61%	7.92%	-13.14%	13.48%	-8.47%	57.81%	-6.95%	-2.93%
Operating Expenses+	822.24M	896.53M	1.02B	1.17B	972.87M	878.68M	899.82M	996.25M	891.66M	1.02B
OpEx % of Revenue	110.26%	99.24%	92.94%	99.58%	93.66%	74.86%	80.93%	59.89%	57.24%	69.1%
Selling, General & Admin	374.13M	421.58M	526.41M	599.45M	538.83M	549.61M	590.75M	689.75M	645.24M	701.52M
SG&A % of Revenue	50.17%	46.67%	48.11%	51.19%	51.87%	46.83%	53.13%	41.47%	41.42%	47.53%
Research & Development	387.15M	412.89M	425.41M	512.83M	394.59M	290.92M	272.7M	270.81M	245.33M	323.96M
R&D % of Revenue	51.92%	45.71%	38.88%	43.8%	37.99%	24.79%	24.53%	16.28%	15.75%	21.95%
Other Operating Expenses	60.96M	62.06M	65.17M	53.76M	39.45M	38.15M	36.36M	35.69M	1.1M	-5.6M
Operating Income+	-208.66M	-147.9M	-99.13M	-175.48M	-112.43M	97.75M	-6.09M	414.12M	420.64M	253.96M
Operating Margin %	-27.98%	-16.37%	-9.06%	-14.99%	-10.82%	8.33%	-0.55%	24.9%	27%	17.21%
Operating Income Growth %	6.97%	29.12%	32.98%	-77.02%	35.93%	186.94%	-106.23%	6901.15%	1.57%	-39.63%
EBITDA+	-114.41M	-49.38M	4.53M	-95.07M	-30.57M	176.4M	71.77M	489.05M	449.17M	281.12M
EBITDA Margin %	-15.34%	-5.47%	0.41%	-8.12%	-2.94%	15.03%	6.46%	29.4%	28.84%	19.05%
EBITDA Growth %	17.52%	56.84%	109.18%	-2197.66%	67.84%	676.97%	-59.31%	581.38%	-8.15%	-37.41%
D&A (Non-Cash Add-back)	94.26M	98.52M	103.66M	80.41M	81.85M	78.65M	77.86M	74.93M	28.53M	27.16M
EBIT	-199.5M	-131.27M	-111.53M	-183.46M	-87.88M	98.95M	-18.09M	444.55M	466.33M	253.96M
Net Interest Income+	-11.14M	-7.36M	-6.2M	375K	-1.7M	-8.81M	-5.41M	7.82M	19.87M	33.03M
Interest Income	3.75M	4.65M	9.24M	13.98M	6.96M	2.41M	7.63M	30.85M	42.45M	45.3M
Interest Expense	14.89M	12.01M	15.44M	13.6M	8.66M	11.22M	13.04M	23.03M	22.58M	12.28M
Other Income/Expense	-5.72M	4.63M	-27.84M	-21.58M	15.89M	-10.02M	-25.04M	7.4M	23.11M	37.49M
Pretax Income+	-214.39M	-143.27M	-126.97M	-197.06M	-96.54M	87.73M	-31.13M	421.52M	443.75M	291.45M
Pretax Margin %	-28.75%	-15.86%	-11.6%	-16.83%	-9.29%	7.47%	-2.8%	25.34%	28.49%	19.75%
Income Tax+	-5.94M	14.67M	12.34M	-436K	14.32M	11.33M	2.02M	-97.64M	71.61M	49.79M
Effective Tax Rate %	97.23%	110.24%	109.72%	99.78%	114.84%	-54.91%	508.44%	84.4%	82.72%	82.92%
Net Income+	-208.44M	-157.94M	-139.31M	-196.62M	-110.86M	-48.17M	-158.27M	355.76M	367.07M	241.66M
Net Margin %	-27.95%	-17.48%	-12.73%	-16.79%	-10.67%	-4.1%	-14.24%	21.39%	23.57%	16.37%
Net Income Growth %	8.24%	24.23%	11.8%	-41.14%	43.62%	56.55%	-228.57%	324.78%	3.18%	-34.16%
Net Income (Continuing)	-208.44M	-157.94M	-139.31M	-196.62M	-110.86M	76.4M	-33.15M	519.16M	372.14M	241.66M
Discontinued Operations	0	0	0	0	0	-124.57M	-125.11M	-163.4M	-5.07M	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.38	-1.03	-0.90	-1.25	-0.70	-0.30	-0.97	2.10	2.17	1.43
EPS Growth %	9.21%	25.36%	12.62%	-38.89%	44%	57.14%	-223.33%	316.49%	3.33%	-34.1%
EPS (Basic)	-1.38	-1.03	-0.90	-1.25	-0.70	-0.30	-0.97	2.14	2.22	1.47
Diluted Shares Outstanding	151.48M	153.41M	155.11M	157.05M	158.8M	160.94M	163.74M	169.73M	169.2M	168.74M
Basic Shares Outstanding	151.48M	153.41M	155.11M	157.05M	158.8M	160.94M	163.74M	166.22M	165.39M	164.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	912.61M	966.06M	983.25M	961.97M	1.11B	1.06B	1.13B	1.49B	1.42B	1.12B
Cash & Short-Term Investments	619.16M	590.72M	539.29M	534.98M	635.03M	536.31M	608.47M	773.49M	751.67M	588.36M
Cash Only	186.38M	191.3M	266.76M	203.77M	272.96M	337.54M	292.47M	457.47M	291.15M	588.36M
Short-Term Investments	310.86M	242.21M	272.53M	331.21M	362.07M	198.77M	315.99M	316.02M	460.52M	0
Accounts Receivable	191.1M	233.59M	300.45M	265.47M	289.54M	326.56M	296.9M	333.18M	389.52M	334.02M
Days Sales Outstanding	93.54	94.38	100.22	82.75	101.74	101.55	97.47	73.11	91.28	82.61
Inventory	63M	93.28M	90.2M	101.8M	125.74M	150.34M	181.42M	186.41M	182.89M	196.63M
Days Inventory Outstanding	174.04	220.01	186.61	205.99	257.38	278.08	303.66	268.89	272.1	355.19
Other Current Assets	0	0	0	0	0	0	43.53M	192.43M	91.28M	0
Total Non-Current Assets+	813.81M	831.17M	841.75M	843.43M	838.76M	962.32M	833.67M	650.72M	640.21M	431.38M
Property, Plant & Equipment	264.79M	284.74M	309.99M	374.55M	481.72M	456.68M	320.46M	318.4M	311.81M	221.72M
Fixed Asset Turnover	2.82x	3.17x	3.53x	3.13x	2.16x	2.57x	3.47x	5.22x	5.00x	6.66x
Goodwill	92.87M	92.87M	92.87M	92.87M	92.87M	92.87M	83.03M	83.03M	83.03M	83.84M
Intangible Assets	318.23M	256.17M	191M	150.64M	111.19M	74.04M	37.68M	1.99M	890K	0
Long-Term Investments	121.93M	157.21M	80.74M	79.39M	24.78M	229.43M	131.61M	39.89M	73.15M	0
Other Non-Current Assets	-31.77M	-58.38M	81.34M	49.42M	41.97M	27.45M	146.32M	11.52M	16.5M	0
Total Assets+	1.73B	1.8B	1.83B	1.81B	1.95B	2.02B	1.96B	2.14B	2.06B	2.49B
Asset Turnover	0.43x	0.50x	0.60x	0.65x	0.53x	0.58x	0.57x	0.78x	0.76x	0.59x
Asset Growth %	-6.97%	4.1%	1.55%	-1.07%	7.99%	3.83%	-2.99%	8.77%	-3.78%	20.99%
Total Current Liabilities+	211.99M	291.12M	339.77M	391.11M	438.26M	471.29M	497.74M	520.22M	465.2M	543.44M
Accounts Payable	46.27M	55.53M	39.77M	54.26M	46.03M	55.72M	32.84M	65.65M	45.63M	0
Days Payables Outstanding	127.84	130.97	82.28	109.79	94.23	103.07	54.97	94.7	67.89	-
Short-Term Debt	3M	3M	2.84M	2.84M	2.84M	3M	3M	3M	0	6.75M
Deferred Revenue (Current)	1.94M	1.96M	3.17M	6.77M	7.51M	6.34M	6.82M	2.73M	1.25M	0
Other Current Liabilities	114.26M	176.07M	226.38M	72.07M	71.18M	77.26M	84.93M	359.99M	70.96M	536.69M
Current Ratio	4.30x	3.32x	2.89x	2.46x	2.53x	2.25x	2.27x	2.86x	3.04x	2.06x
Quick Ratio	4.01x	3.00x	2.63x	2.20x	2.25x	1.93x	1.91x	2.50x	2.65x	1.70x
Cash Conversion Cycle	139.74	183.42	204.55	178.95	264.89	276.56	346.15	247.3	295.48	-
Total Non-Current Liabilities+	304.95M	303.3M	313.95M	328.85M	444.49M	440.61M	422.48M	413.32M	125.39M	124.26M
Long-Term Debt	280.67M	278.44M	276.46M	274.3M	272.12M	292.8M	290.27M	287.73M	0	63.25M
Capital Lease Obligations	0	0	0	5.34M	119.46M	104.16M	76.29M	75.71M	69.37M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	-4.78M	0	0
Other Non-Current Liabilities	17.16M	19.2M	27.96M	27.14M	36.51M	32.16M	55.93M	49.88M	56.02M	61.01M
Total Liabilities	516.94M	594.42M	653.72M	719.96M	882.75M	911.9M	920.23M	933.54M	590.59M	667.7M
Total Debt+	283.67M	281.44M	279.31M	290.95M	410.16M	416.21M	379.44M	372.19M	75.54M	70M
Net Debt	97.29M	90.14M	12.55M	87.17M	137.2M	78.66M	86.96M	-85.28M	-215.61M	-518.36M
Debt / Equity	0.23x	0.23x	0.24x	0.27x	0.38x	0.37x	0.36x	0.31x	0.05x	0.04x
Debt / EBITDA	-	-	61.63x	-	-	2.36x	5.29x	0.76x	0.17x	0.25x
Net Debt / EBITDA	-	-	2.77x	-	-	0.45x	1.21x	-0.17x	-0.48x	-1.84x
Interest Coverage	-14.01x	-12.32x	-6.42x	-12.90x	-12.98x	8.71x	-0.47x	17.98x	18.63x	20.69x
Total Equity+	1.21B	1.2B	1.17B	1.09B	1.07B	1.11B	1.04B	1.2B	1.46B	1.82B
Equity Growth %	-7.97%	-0.55%	-2.62%	-7.33%	-1.7%	4.27%	-6.19%	15.23%	21.81%	24.19%
Book Value per Share	7.98	7.84	7.55	6.91	6.72	6.91	6.37	7.09	8.66	10.78
Total Shareholders' Equity	1.21B	1.2B	1.17B	1.09B	1.07B	1.11B	1.04B	1.2B	1.46B	1.82B
Common Stock	1.54M	1.56M	1.58M	1.6M	1.62M	1.66M	1.69M	1.73M	1.77M	1.81M
Retained Earnings	-947.94M	-1.04B	-1.19B	-1.38B	-1.49B	-1.54B	-1.7B	-1.34B	-976.46M	-734.79M
Treasury Stock	-72.64M	-89.35M	-108.97M	-118.39M	-126.09M	-142.66M	-160.86M	-189.34M	-419.25M	0
Accumulated OCI	-3.27M	-3.79M	-3.28M	-1.82M	-1.35M	-3.72M	-10.89M	-3.11M	-1.97M	-2.1M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-63.8M	19.19M	99.28M	72.08M	82.84M	101.72M	21.04M	401.35M	439.12M	520.8K
Operating CF Margin %	-8.56%	2.12%	9.07%	6.16%	7.98%	8.67%	1.89%	24.13%	28.19%	0.04%
Operating CF Growth %	-58.08%	130.08%	417.36%	-27.4%	14.94%	22.78%	-79.31%	1807.21%	9.41%	-99.88%
Net Income	-208.44M	-157.94M	-139.31M	-196.62M	-110.86M	-48.17M	-158.27M	355.76M	367.07M	241.66M
Depreciation & Amortization	94.26M	98.52M	103.66M	80.41M	81.85M	78.65M	77.86M	74.93M	28.53M	0
Stock-Based Compensation	94.4M	83.92M	105.36M	100.98M	90.16M	87.62M	94.25M	100.91M	96.64M	0
Deferred Taxes	-9.69M	7.23M	10.62M	-319K	9.98M	5.08M	-32.8M	-99.9M	40.52M	0
Other Non-Cash Items	-7.12M	-7.66M	26.37M	22.22M	-1.43M	4.08M	27.28M	6.33M	4.51M	-241.14M
Working Capital Changes	-27.2M	-4.88M	-7.42M	65.41M	13.13M	-25.55M	12.71M	-36.66M	-98.15M	0
Change in Receivables	-35.62M	-42.49M	-58.63M	29.98M	-18.05M	-38.01M	25.25M	-44.51M	-56.34M	0
Change in Inventory	-26.38M	-30.19M	-2.67M	-13.08M	-22.93M	-24.77M	-31.02M	-2.71M	3.09M	0
Change in Payables	45.87M	72.66M	46.74M	34.85M	59.04M	43.31M	15.53M	23.01M	-57.97M	0
Cash from Investing+	127.24M	-18.36M	-22.2M	-141.83M	-11.48M	-66.2M	-64.54M	53.36M	-111.31M	295.5K
Capital Expenditures	-43.66M	-51.3M	-69.43M	-90.94M	-42.22M	-29.02M	-38.26M	-48.05M	-33.48M	0
CapEx % of Revenue	5.85%	5.68%	6.34%	7.77%	4.06%	2.47%	3.44%	2.89%	2.15%	-
Acquisitions	-15M	162K	507K	-7.97M	2.75M	-713K	485K	0	97.98M	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	194K	162K	507K	10M	4.53M	8.94M	1.27M	354K	461K	295.5K
Cash from Financing+	-58.17M	4.08M	-1.62M	6.76M	-2.17M	29.07M	-1.57M	-289.71M	-494.14M	12.4K
Debt Issued (Net)	-65.81M	0	-743K	-2.84M	-2.84M	20.32M	-3M	-3M	-291.79M	0
Equity Issued (Net)	0	0	0	1000K	672K	1000K	1000K	-1000K	-1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-13.47M	-16.43M	-19.62M	-9.32M	-7.7M	-16.57M	-18.2M	-28.47M	-200.28M	0
Other Financing	7.64M	4.08M	-877K	0	0	0	0	-275M	-2.06M	12.4K
Net Change in Cash	5.27M	4.92M	75.47M	-62.99M	69.19M	64.58M	-45.07M	165M	-166.32M	828.7K
Free Cash Flow+	-107.46M	-32.11M	29.85M	-18.86M	40.62M	72.69M	-17.21M	353.31M	405.64M	520.8K
FCF Margin %	-14.41%	-3.55%	2.73%	-1.61%	3.91%	6.19%	-1.55%	21.24%	26.04%	0.04%
FCF Growth %	-15.25%	70.12%	192.96%	-163.2%	315.34%	78.95%	-123.68%	2152.79%	14.81%	-99.87%
FCF per Share	-0.71	-0.21	0.19	-0.12	0.26	0.45	-0.11	2.08	2.40	0.00
FCF Conversion (FCF/Net Income)	0.31x	-0.12x	-0.71x	-0.37x	-0.75x	-2.11x	-0.13x	1.13x	1.20x	0.00x
Interest Paid	12.46M	11.14M	12.53M	0	8.29M	6.9M	13.56M	22.75M	23.01M	0
Taxes Paid	5.53M	2.99M	754K	0	620K	1.89M	20.75M	44.24M	2.59M	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-16.52%	-13.1%	-11.74%	-17.43%	-10.3%	-4.42%	-14.68%	31.67%	27.52%	14.72%
Return on Invested Capital (ROIC)	-11.22%	-8.53%	-6%	-11.17%	-7.1%	6.12%	-0.39%	27.63%	26.66%	14.94%
Gross Margin	82.28%	82.87%	83.88%	84.59%	82.83%	83.19%	80.39%	84.79%	84.25%	86.31%
Net Margin	-27.95%	-17.48%	-12.73%	-16.79%	-10.67%	-4.1%	-14.24%	21.39%	23.57%	16.37%
Debt / Equity	0.23x	0.23x	0.24x	0.27x	0.38x	0.37x	0.36x	0.31x	0.05x	0.04x
Interest Coverage	-14.01x	-12.32x	-6.42x	-12.90x	-12.98x	8.71x	-0.47x	17.98x	18.63x	20.69x
FCF Conversion	0.31x	-0.12x	-0.71x	-0.37x	-0.75x	-2.11x	-0.13x	1.13x	1.20x	0.00x
Revenue Growth	18.68%	21.15%	21.13%	7.01%	-11.29%	13%	-5.28%	49.61%	-6.36%	-5.25%

US Stock Screener

...

Alkermes plc (ALKS) 10-Year Financial Performance & Capital Metrics

ALKS •

HealthcareBiotechnologyCommercial Specialty Pharma

Revenue $1.48B -5.2%
EBITDA $281M -37.4%
Net Income $242M -34.2%
EPS (Diluted) 1.43 -34.1%
Gross Margin 86.31% +2.4%
EBITDA Margin 19.05% -33.9%
Operating Margin 17.21% -36.3%
Net Margin 16.37% -30.5%
ROE 14.72% -46.5%
ROIC 14.94% -44.0%
Debt/Equity 0.04 -25.4%
Interest Coverage 20.69 +11.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Excellent 3Y average ROE of 24.6%

✗Weaknesses

✗Low quality earnings: Net income not backed by cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y8.91%

5Y7.28%

3Y9.9%

TTM-5.25%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-34.16%

EPS CAGR

10Y-

5Y-

3Y-

TTM-34.1%

ROCE

10Y Avg2.39%

5Y Avg14.69%

3Y Avg22.49%

Latest14.37%

Peer Comparison

Commercial Specialty Pharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ALKSAlkermes plc	4.98B	30.10	21.05	-5.25%	16.37%	13.28%	0.01%	0.04
ADMAADMA Biologics, Inc.	3.71B	15.57	19.22	65.15%	42.87%	48.57%	2.97%	0.24
UTHRUnited Therapeutics Corporation	21.99B	503.90	18.09	10.61%	41.94%	18.81%	4.73%
PCSAProcessa Pharmaceuticals, Inc.	114.71M	2.17	-0.56			-221.71%		0.04
UNCYUnicycive Therapeutics, Inc.	144.49M	6.93	-1.24	-100%		-89.15%		0.10
PTHSPelthos Therapeutics Inc.	85.29M	26.36	-1.95		-318.41%	-40.48%
MISTMilestone Pharmaceuticals Inc.	145.64M	1.71	-2.55	-100%		-282.97%		4.17
AMRNAmarin Corporation plc	5.74B	13.80	-3.45	-25.51%	-38.01%	-18.78%		0.02

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	745.69M	903.37M	1.09B	1.17B	1.04B	1.17B	1.11B	1.66B	1.56B	1.48B
Revenue Growth %	18.68%	21.15%	21.13%	7.01%	-11.29%	13%	-5.28%	49.61%	-6.36%	-5.25%
Cost of Goods Sold+	132.12M	154.75M	176.42M	180.38M	178.32M	197.32M	218.07M	253.04M	245.33M	202.06M
COGS % of Revenue	17.72%	17.13%	16.12%	15.41%	17.17%	16.81%	19.61%	15.21%	15.75%	13.69%
Gross Profit+	613.57M	748.63M	917.85M	990.56M	860.44M	976.43M	893.73M	1.41B	1.31B	1.27B
Gross Margin %	82.28%	82.87%	83.88%	84.59%	82.83%	83.19%	80.39%	84.79%	84.25%	86.31%
Gross Profit Growth %	25.39%	22.01%	22.61%	7.92%	-13.14%	13.48%	-8.47%	57.81%	-6.95%	-2.93%
Operating Expenses+	822.24M	896.53M	1.02B	1.17B	972.87M	878.68M	899.82M	996.25M	891.66M	1.02B
OpEx % of Revenue	110.26%	99.24%	92.94%	99.58%	93.66%	74.86%	80.93%	59.89%	57.24%	69.1%
Selling, General & Admin	374.13M	421.58M	526.41M	599.45M	538.83M	549.61M	590.75M	689.75M	645.24M	701.52M
SG&A % of Revenue	50.17%	46.67%	48.11%	51.19%	51.87%	46.83%	53.13%	41.47%	41.42%	47.53%
Research & Development	387.15M	412.89M	425.41M	512.83M	394.59M	290.92M	272.7M	270.81M	245.33M	323.96M
R&D % of Revenue	51.92%	45.71%	38.88%	43.8%	37.99%	24.79%	24.53%	16.28%	15.75%	21.95%
Other Operating Expenses	60.96M	62.06M	65.17M	53.76M	39.45M	38.15M	36.36M	35.69M	1.1M	-5.6M
Operating Income+	-208.66M	-147.9M	-99.13M	-175.48M	-112.43M	97.75M	-6.09M	414.12M	420.64M	253.96M
Operating Margin %	-27.98%	-16.37%	-9.06%	-14.99%	-10.82%	8.33%	-0.55%	24.9%	27%	17.21%
Operating Income Growth %	6.97%	29.12%	32.98%	-77.02%	35.93%	186.94%	-106.23%	6901.15%	1.57%	-39.63%
EBITDA+	-114.41M	-49.38M	4.53M	-95.07M	-30.57M	176.4M	71.77M	489.05M	449.17M	281.12M
EBITDA Margin %	-15.34%	-5.47%	0.41%	-8.12%	-2.94%	15.03%	6.46%	29.4%	28.84%	19.05%
EBITDA Growth %	17.52%	56.84%	109.18%	-2197.66%	67.84%	676.97%	-59.31%	581.38%	-8.15%	-37.41%
D&A (Non-Cash Add-back)	94.26M	98.52M	103.66M	80.41M	81.85M	78.65M	77.86M	74.93M	28.53M	27.16M
EBIT	-199.5M	-131.27M	-111.53M	-183.46M	-87.88M	98.95M	-18.09M	444.55M	466.33M	253.96M
Net Interest Income+	-11.14M	-7.36M	-6.2M	375K	-1.7M	-8.81M	-5.41M	7.82M	19.87M	33.03M
Interest Income	3.75M	4.65M	9.24M	13.98M	6.96M	2.41M	7.63M	30.85M	42.45M	45.3M
Interest Expense	14.89M	12.01M	15.44M	13.6M	8.66M	11.22M	13.04M	23.03M	22.58M	12.28M
Other Income/Expense	-5.72M	4.63M	-27.84M	-21.58M	15.89M	-10.02M	-25.04M	7.4M	23.11M	37.49M
Pretax Income+	-214.39M	-143.27M	-126.97M	-197.06M	-96.54M	87.73M	-31.13M	421.52M	443.75M	291.45M
Pretax Margin %	-28.75%	-15.86%	-11.6%	-16.83%	-9.29%	7.47%	-2.8%	25.34%	28.49%	19.75%
Income Tax+	-5.94M	14.67M	12.34M	-436K	14.32M	11.33M	2.02M	-97.64M	71.61M	49.79M
Effective Tax Rate %	97.23%	110.24%	109.72%	99.78%	114.84%	-54.91%	508.44%	84.4%	82.72%	82.92%
Net Income+	-208.44M	-157.94M	-139.31M	-196.62M	-110.86M	-48.17M	-158.27M	355.76M	367.07M	241.66M
Net Margin %	-27.95%	-17.48%	-12.73%	-16.79%	-10.67%	-4.1%	-14.24%	21.39%	23.57%	16.37%
Net Income Growth %	8.24%	24.23%	11.8%	-41.14%	43.62%	56.55%	-228.57%	324.78%	3.18%	-34.16%
Net Income (Continuing)	-208.44M	-157.94M	-139.31M	-196.62M	-110.86M	76.4M	-33.15M	519.16M	372.14M	241.66M
Discontinued Operations	0	0	0	0	0	-124.57M	-125.11M	-163.4M	-5.07M	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.38	-1.03	-0.90	-1.25	-0.70	-0.30	-0.97	2.10	2.17	1.43
EPS Growth %	9.21%	25.36%	12.62%	-38.89%	44%	57.14%	-223.33%	316.49%	3.33%	-34.1%
EPS (Basic)	-1.38	-1.03	-0.90	-1.25	-0.70	-0.30	-0.97	2.14	2.22	1.47
Diluted Shares Outstanding	151.48M	153.41M	155.11M	157.05M	158.8M	160.94M	163.74M	169.73M	169.2M	168.74M
Basic Shares Outstanding	151.48M	153.41M	155.11M	157.05M	158.8M	160.94M	163.74M	166.22M	165.39M	164.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	912.61M	966.06M	983.25M	961.97M	1.11B	1.06B	1.13B	1.49B	1.42B	1.12B
Cash & Short-Term Investments	619.16M	590.72M	539.29M	534.98M	635.03M	536.31M	608.47M	773.49M	751.67M	588.36M
Cash Only	186.38M	191.3M	266.76M	203.77M	272.96M	337.54M	292.47M	457.47M	291.15M	588.36M
Short-Term Investments	310.86M	242.21M	272.53M	331.21M	362.07M	198.77M	315.99M	316.02M	460.52M	0
Accounts Receivable	191.1M	233.59M	300.45M	265.47M	289.54M	326.56M	296.9M	333.18M	389.52M	334.02M
Days Sales Outstanding	93.54	94.38	100.22	82.75	101.74	101.55	97.47	73.11	91.28	82.61
Inventory	63M	93.28M	90.2M	101.8M	125.74M	150.34M	181.42M	186.41M	182.89M	196.63M
Days Inventory Outstanding	174.04	220.01	186.61	205.99	257.38	278.08	303.66	268.89	272.1	355.19
Other Current Assets	0	0	0	0	0	0	43.53M	192.43M	91.28M	0
Total Non-Current Assets+	813.81M	831.17M	841.75M	843.43M	838.76M	962.32M	833.67M	650.72M	640.21M	431.38M
Property, Plant & Equipment	264.79M	284.74M	309.99M	374.55M	481.72M	456.68M	320.46M	318.4M	311.81M	221.72M
Fixed Asset Turnover	2.82x	3.17x	3.53x	3.13x	2.16x	2.57x	3.47x	5.22x	5.00x	6.66x
Goodwill	92.87M	92.87M	92.87M	92.87M	92.87M	92.87M	83.03M	83.03M	83.03M	83.84M
Intangible Assets	318.23M	256.17M	191M	150.64M	111.19M	74.04M	37.68M	1.99M	890K	0
Long-Term Investments	121.93M	157.21M	80.74M	79.39M	24.78M	229.43M	131.61M	39.89M	73.15M	0
Other Non-Current Assets	-31.77M	-58.38M	81.34M	49.42M	41.97M	27.45M	146.32M	11.52M	16.5M	0
Total Assets+	1.73B	1.8B	1.83B	1.81B	1.95B	2.02B	1.96B	2.14B	2.06B	2.49B
Asset Turnover	0.43x	0.50x	0.60x	0.65x	0.53x	0.58x	0.57x	0.78x	0.76x	0.59x
Asset Growth %	-6.97%	4.1%	1.55%	-1.07%	7.99%	3.83%	-2.99%	8.77%	-3.78%	20.99%
Total Current Liabilities+	211.99M	291.12M	339.77M	391.11M	438.26M	471.29M	497.74M	520.22M	465.2M	543.44M
Accounts Payable	46.27M	55.53M	39.77M	54.26M	46.03M	55.72M	32.84M	65.65M	45.63M	0
Days Payables Outstanding	127.84	130.97	82.28	109.79	94.23	103.07	54.97	94.7	67.89	-
Short-Term Debt	3M	3M	2.84M	2.84M	2.84M	3M	3M	3M	0	6.75M
Deferred Revenue (Current)	1.94M	1.96M	3.17M	6.77M	7.51M	6.34M	6.82M	2.73M	1.25M	0
Other Current Liabilities	114.26M	176.07M	226.38M	72.07M	71.18M	77.26M	84.93M	359.99M	70.96M	536.69M
Current Ratio	4.30x	3.32x	2.89x	2.46x	2.53x	2.25x	2.27x	2.86x	3.04x	2.06x
Quick Ratio	4.01x	3.00x	2.63x	2.20x	2.25x	1.93x	1.91x	2.50x	2.65x	1.70x
Cash Conversion Cycle	139.74	183.42	204.55	178.95	264.89	276.56	346.15	247.3	295.48	-
Total Non-Current Liabilities+	304.95M	303.3M	313.95M	328.85M	444.49M	440.61M	422.48M	413.32M	125.39M	124.26M
Long-Term Debt	280.67M	278.44M	276.46M	274.3M	272.12M	292.8M	290.27M	287.73M	0	63.25M
Capital Lease Obligations	0	0	0	5.34M	119.46M	104.16M	76.29M	75.71M	69.37M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	-4.78M	0	0
Other Non-Current Liabilities	17.16M	19.2M	27.96M	27.14M	36.51M	32.16M	55.93M	49.88M	56.02M	61.01M
Total Liabilities	516.94M	594.42M	653.72M	719.96M	882.75M	911.9M	920.23M	933.54M	590.59M	667.7M
Total Debt+	283.67M	281.44M	279.31M	290.95M	410.16M	416.21M	379.44M	372.19M	75.54M	70M
Net Debt	97.29M	90.14M	12.55M	87.17M	137.2M	78.66M	86.96M	-85.28M	-215.61M	-518.36M
Debt / Equity	0.23x	0.23x	0.24x	0.27x	0.38x	0.37x	0.36x	0.31x	0.05x	0.04x
Debt / EBITDA	-	-	61.63x	-	-	2.36x	5.29x	0.76x	0.17x	0.25x
Net Debt / EBITDA	-	-	2.77x	-	-	0.45x	1.21x	-0.17x	-0.48x	-1.84x
Interest Coverage	-14.01x	-12.32x	-6.42x	-12.90x	-12.98x	8.71x	-0.47x	17.98x	18.63x	20.69x
Total Equity+	1.21B	1.2B	1.17B	1.09B	1.07B	1.11B	1.04B	1.2B	1.46B	1.82B
Equity Growth %	-7.97%	-0.55%	-2.62%	-7.33%	-1.7%	4.27%	-6.19%	15.23%	21.81%	24.19%
Book Value per Share	7.98	7.84	7.55	6.91	6.72	6.91	6.37	7.09	8.66	10.78
Total Shareholders' Equity	1.21B	1.2B	1.17B	1.09B	1.07B	1.11B	1.04B	1.2B	1.46B	1.82B
Common Stock	1.54M	1.56M	1.58M	1.6M	1.62M	1.66M	1.69M	1.73M	1.77M	1.81M
Retained Earnings	-947.94M	-1.04B	-1.19B	-1.38B	-1.49B	-1.54B	-1.7B	-1.34B	-976.46M	-734.79M
Treasury Stock	-72.64M	-89.35M	-108.97M	-118.39M	-126.09M	-142.66M	-160.86M	-189.34M	-419.25M	0
Accumulated OCI	-3.27M	-3.79M	-3.28M	-1.82M	-1.35M	-3.72M	-10.89M	-3.11M	-1.97M	-2.1M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-63.8M	19.19M	99.28M	72.08M	82.84M	101.72M	21.04M	401.35M	439.12M	520.8K
Operating CF Margin %	-8.56%	2.12%	9.07%	6.16%	7.98%	8.67%	1.89%	24.13%	28.19%	0.04%
Operating CF Growth %	-58.08%	130.08%	417.36%	-27.4%	14.94%	22.78%	-79.31%	1807.21%	9.41%	-99.88%
Net Income	-208.44M	-157.94M	-139.31M	-196.62M	-110.86M	-48.17M	-158.27M	355.76M	367.07M	241.66M
Depreciation & Amortization	94.26M	98.52M	103.66M	80.41M	81.85M	78.65M	77.86M	74.93M	28.53M	0
Stock-Based Compensation	94.4M	83.92M	105.36M	100.98M	90.16M	87.62M	94.25M	100.91M	96.64M	0
Deferred Taxes	-9.69M	7.23M	10.62M	-319K	9.98M	5.08M	-32.8M	-99.9M	40.52M	0
Other Non-Cash Items	-7.12M	-7.66M	26.37M	22.22M	-1.43M	4.08M	27.28M	6.33M	4.51M	-241.14M
Working Capital Changes	-27.2M	-4.88M	-7.42M	65.41M	13.13M	-25.55M	12.71M	-36.66M	-98.15M	0
Change in Receivables	-35.62M	-42.49M	-58.63M	29.98M	-18.05M	-38.01M	25.25M	-44.51M	-56.34M	0
Change in Inventory	-26.38M	-30.19M	-2.67M	-13.08M	-22.93M	-24.77M	-31.02M	-2.71M	3.09M	0
Change in Payables	45.87M	72.66M	46.74M	34.85M	59.04M	43.31M	15.53M	23.01M	-57.97M	0
Cash from Investing+	127.24M	-18.36M	-22.2M	-141.83M	-11.48M	-66.2M	-64.54M	53.36M	-111.31M	295.5K
Capital Expenditures	-43.66M	-51.3M	-69.43M	-90.94M	-42.22M	-29.02M	-38.26M	-48.05M	-33.48M	0
CapEx % of Revenue	5.85%	5.68%	6.34%	7.77%	4.06%	2.47%	3.44%	2.89%	2.15%	-
Acquisitions	-15M	162K	507K	-7.97M	2.75M	-713K	485K	0	97.98M	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	194K	162K	507K	10M	4.53M	8.94M	1.27M	354K	461K	295.5K
Cash from Financing+	-58.17M	4.08M	-1.62M	6.76M	-2.17M	29.07M	-1.57M	-289.71M	-494.14M	12.4K
Debt Issued (Net)	-65.81M	0	-743K	-2.84M	-2.84M	20.32M	-3M	-3M	-291.79M	0
Equity Issued (Net)	0	0	0	1000K	672K	1000K	1000K	-1000K	-1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-13.47M	-16.43M	-19.62M	-9.32M	-7.7M	-16.57M	-18.2M	-28.47M	-200.28M	0
Other Financing	7.64M	4.08M	-877K	0	0	0	0	-275M	-2.06M	12.4K
Net Change in Cash	5.27M	4.92M	75.47M	-62.99M	69.19M	64.58M	-45.07M	165M	-166.32M	828.7K
Free Cash Flow+	-107.46M	-32.11M	29.85M	-18.86M	40.62M	72.69M	-17.21M	353.31M	405.64M	520.8K
FCF Margin %	-14.41%	-3.55%	2.73%	-1.61%	3.91%	6.19%	-1.55%	21.24%	26.04%	0.04%
FCF Growth %	-15.25%	70.12%	192.96%	-163.2%	315.34%	78.95%	-123.68%	2152.79%	14.81%	-99.87%
FCF per Share	-0.71	-0.21	0.19	-0.12	0.26	0.45	-0.11	2.08	2.40	0.00
FCF Conversion (FCF/Net Income)	0.31x	-0.12x	-0.71x	-0.37x	-0.75x	-2.11x	-0.13x	1.13x	1.20x	0.00x
Interest Paid	12.46M	11.14M	12.53M	0	8.29M	6.9M	13.56M	22.75M	23.01M	0
Taxes Paid	5.53M	2.99M	754K	0	620K	1.89M	20.75M	44.24M	2.59M	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-16.52%	-13.1%	-11.74%	-17.43%	-10.3%	-4.42%	-14.68%	31.67%	27.52%	14.72%
Return on Invested Capital (ROIC)	-11.22%	-8.53%	-6%	-11.17%	-7.1%	6.12%	-0.39%	27.63%	26.66%	14.94%
Gross Margin	82.28%	82.87%	83.88%	84.59%	82.83%	83.19%	80.39%	84.79%	84.25%	86.31%
Net Margin	-27.95%	-17.48%	-12.73%	-16.79%	-10.67%	-4.1%	-14.24%	21.39%	23.57%	16.37%
Debt / Equity	0.23x	0.23x	0.24x	0.27x	0.38x	0.37x	0.36x	0.31x	0.05x	0.04x
Interest Coverage	-14.01x	-12.32x	-6.42x	-12.90x	-12.98x	8.71x	-0.47x	17.98x	18.63x	20.69x
FCF Conversion	0.31x	-0.12x	-0.71x	-0.37x	-0.75x	-2.11x	-0.13x	1.13x	1.20x	0.00x
Revenue Growth	18.68%	21.15%	21.13%	7.01%	-11.29%	13%	-5.28%	49.61%	-6.36%	-5.25%

Alkermes plc (ALKS) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare ALKS vs Peers

vs UTHR

vs ZLAB

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Alkermes plc (ALKS) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare ALKS vs Peers

vs UTHR

vs ZLAB

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios